Cargando…

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study

OBJECTIVE: To describe adherence, persistence, discontinuation, restarting, switching, dosing, and health care costs among patients with psoriatic arthritis (PsA) treated with ixekizumab (IXE). METHODS: MarketScan administrative claims databases were used to select adults (≥18 years) initiating IXE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murage, Mwangi J., Princic, Nicole, Park, Julie, Malatestinic, William, Zhu, Baojin, Atiya, Bilal, Kern, Scott A., Stenger, Keri B., Sprabery, Aubrey Trevelin, Ogdie, Alexis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672175/ https://www.ncbi.nlm.nih.gov/pubmed/34550647 http://dx.doi.org/10.1002/acr2.11347

Ejemplares similares

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs
por: Murage, Mwangi J, et al.
Publicado: (2022)

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
por: Eder, Lihi, et al.
Publicado: (2022)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
por: Deodhar, Atul A, et al.
Publicado: (2022)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
por: Kirkham, Bruce, et al.
Publicado: (2021)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire
por: Tillett, William, et al.
Publicado: (2019)

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
por: Smolen, Josef S., et al.
Publicado: (2020)

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
por: Chandran, Vinod, et al.
Publicado: (2020)

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
por: Miller, John, et al.
Publicado: (2021)

Psoriatic arthritis: prospects for the future
por: Hackett, Simon, et al.
Publicado: (2022)

Obesity and Psoriatic Arthritis: A Narrative Review
por: Kumthekar, Anand, et al.
Publicado: (2020)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
por: Murage, Mwangi J, et al.
Publicado: (2018)

Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
por: Joven, Beatriz, et al.
Publicado: (2023)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
por: Gottlieb, Alice B., et al.
Publicado: (2023)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
por: Combe, Bernard, et al.
Publicado: (2021)

Probiotic Use and Psoriatic Arthritis Disease Activity
por: Grinnell, Madison, et al.
Publicado: (2020)

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
por: Karmacharya, Paras, et al.
Publicado: (2021)

Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry
por: Mease, Philip J, et al.
Publicado: (2019)

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
por: Braña, Ignacio, et al.
Publicado: (2023)

Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2021)

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(®) Databases
por: Leonardi, Craig, et al.
Publicado: (2022)

Classification and Outcome Measures for Psoriatic Arthritis
por: Leung, Ying Ying, et al.
Publicado: (2018)

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
por: Mease, Philip, et al.
Publicado: (2019)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2023)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence
por: Coates, Laura C., et al.
Publicado: (2022)

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
por: Gladman, Dafna D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_12lib3q3tin6a43p7748aandag